EX NOBEL COMMITTEE CHAIRMAN SELECTED FOR NEW SEAT ON DIAMYD MEDICAL’S BOARD

Press Release, Stockholm, Sweden – September 28, 2006 – Diamyd Medical AB (SWEDEN OMXS: DIAM B; USA ADR: DMYDY)

Diamyd Medical today announces that Professor Hans Wigzell MD, Ph.D has agreed, pending shareholder approval, to serve as a Director on the Board at Diamyd Medical AB. Having recently presented positive results in a phase II trial in type 1-diabetes patients with the GAD-based therapeutic Diamyd™, the appointment of professor Wigzell brings another experienced advisor to Diamyd as the Company now plans for international clinical trials and continues its discussions with potential licensing partners. “The addition of Hans Wigzell to our Board of Directors greatly enhances the Company’s network and knowledge base within biotech-pharma projects, businesses and science”, says Anders Essen-Moller, president of Diamyd Medical. “Professor Wigzell is one of the most forward thinking and creative persons of our time. His insight and advice will prove to be invaluable when bridging business with science as we continue to build our Company.” “I have followed Diamyd Medical closely over the past 10 years and I am excited by the recent Phase II results from the type 1-diabetes study and am committed to do my best to contribute to this innovative and emerging company’s continued success”, says professor Wigzell. Professor Wigzell will be adjuncted to Diamyd Medical’s Board with immediate effect and formally proposed as a Director, up for election by the shareholders, at the next general assembly of shareholders on December 11. --------------------------------------------------------------------------------------------------------------------- About Professor Hans Wigzell Hans Wigzell, MD, Ph.D was born in 1938 and appointed professor in immunology at the Uppsala University in 1972 and at the Karolinska Institute in 1982. Wigzell served as President of the Karolinska Institute between 1995 and 2004, as Chairman of the Nobel Prize Committee 1990-1992 and as President of the Nobel Assembly at the Karolinska Institute in1997. Wigzell is currently Chief Scientific Advisor to the Swedish Government, and Senior Strategic Advisor to the Karolinska Institute. Wigzell is a scientific adviser to Biocon, Bangalore, India; and HBM Partners, Zürich, Swizerland and serves at the commercial Boards of Karolinska Innovation AB, Karolinska Development I and II AB, Biovitrum AB, Stockholm, Sweden; Raysearch AB, Stockholm, Sweden; and Intercell, Vienna, Austria.